ACIU
HealthcareAC Immune SA
$3.52
+$0.16 (+4.76%)
Jan 5, 2026
Price History (1Y)
Analysis
AC Immune SA is a biotechnology company operating in the healthcare sector. The company has a market capitalization of $354.11 million and employs 133 individuals. The financial health of AC Immune SA presents challenges, with negative profitability metrics. The company's gross margin is 0.0%, while its operating margin and profit margin are -1671.9% and 0.0%, respectively. Returns on equity and assets are also negative, at -74.6% and -22.0%, respectively. The balance sheet indicates a relatively low level of debt ($4.66 million) compared to cash reserves ($108.47 million), with a current ratio of 1.16. AC Immune SA's valuation is driven by its P/E ratio of -4.60, indicating significant losses in the trailing twelve months. Revenue growth has been substantial, contracting by 96.3% year-over-year, while earnings growth is not reported (N/A). Dividend yield and payout ratio are also N/A.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Visit website →Key Statistics
- Market Cap
- $354.11M
- P/E Ratio
- N/A
- 52-Week High
- $4.00
- 52-Week Low
- $1.43
- Avg Volume
- 697.18K
- Beta
- 1.62
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Switzerland
- Employees
- 133